Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Gro...(US cents pershare) this represents total...)

Dividend payments will be made in Pounds Sterling to Ordinary Shareholders and US Dollars to American Depositary Share ("ADS") holders. A dividend of 3.3151 pence per ordinary share and 19.407 US cents per ADS, respectively, will be paid. The Board has resolved to pay the dividend on April 3, 2008 to persons whose names appear on the register of members of the Company at the close of business on March 14, 2008.

Shire intends to pursue a progressive dividend policy.

Redemption of Exchangeable Shares

On February 12, 2008, a subsidiary of Shire exercised a redemption call right and purchased each exchangeable share of Shire Acquisition Inc. remaining in public ownership. Exchangeable shareholders received either three ordinary shares of Shire plc or one ADS (representing three ordinary shares of Shire plc) for each Exchangeable Share held. Exchangeable Shares were issued to Canadian resident shareholders of Biochem Pharma Inc. in 2001 as consideration for the acquisition by the Shire group of Biochem Pharma Inc. The Exchangeable Shares, which were listed on the Toronto Stock Exchange, have now been de-listed from the Toronto Stock Exchange.

Changes in Executive and Non-Executive Directors

In January 2007 Dr Jeffrey Leiden, MD, PhD joined Shire's Board of Directors as a Non-Executive Director and has been a member of the Remuneration and Nominations Committee since July 2007.

In May 2007 the Hon. James Grant, Q.C. retired from the Board following completion of his term of office.

In October 2007 David Mott joined Shire's Board of Directors as a Non-Executive Director and was appointed to Shire's Audit, Compliance and Risk Committee on December 12, 2007. Mr Mott is Chief Executive Officer and President of MedImmune, Inc, a role he was appointed t
'/>"/>